Borderline Ovarian Cancer: A Case Study Of Fifteen Patients Treated At Mountain States Tumor Institute In Boise, Idaho
Over a fourteen-year period, 1970-1984, 213 patients with malignant ovarian tumors were seen at Mountain States Tumor Institute in Boise, Idaho. Of these, fifteen (7%) were pathologically diagnosed with ovarian tumors of borderline malignancy. Seven of the cases were Stage I, two were Stage II, six were Stage III, and no Stage IV patients were diagnosed. Ten patients were diagnosed as serous cystadenocarcinomas of borderline malignancy and five were diagnosed as borderline mucinous tumors. A varied regimen of both chemotherapy and radiation treatment was administered to the patients. Twelve patients received adjuvant therapy following surgery, six received chemotherapy. Of these, two were Stage I and four were Stage III. Six patients were administered radiation therapy (of these two were Stage I, two were Stage II, and two were Stage III). Three patients received no treament, all were Stage I. The mean age for all borderline patients was 40.1 years. Seven had bilateral tumors, while eight were unilateral. Four patients had second look laparotomies following chemotherapy. Only one had recurrent disease; the other three showed no evidence of cancer. The mean followup was 73 months and the five-year survival rate was 100%.